-
Innovation Group: Osemitamab (TST001), a new drug targeting Claudin18.2 antibody for the treatment o...
This is the second orphan drug designation for Osemitamab(TST001) after it received FDA orphan drug designation for the treatment of gastric cancer an...
2023-03-31 13:44 -
Maxpro: Completed merger with SPAC Maxpro and listed on Nasdaq
Guancomibo opens new cooperation.
2023-03-31 13:43 -
Jianxin Biology: Completed the B round of financing to accelerate the phase I clinical study of the ...
New progress in Health Bioharvest.
2023-03-21 11:05 -
Heavy! The new indication of the innovative ADC SHR-A1811 is intended to be included in the breakthr...
New progress of ADC research and development of Hengrui
2023-03-21 11:03 -
Double Anti selling 546 million yuan! With a total revenue of 1.1 billion yuan in 2022, Kangfang Bio...
Can you pick the high hanging fruit of double resistance?
2023-03-21 11:01 -
Chuangxiang: izokibep HS clinical phase 2b/3 data released
Chuang Sound biology overseas progress.
2023-03-21 10:59 -
2023 Patent Apocalypse, Generics Get a Boost? Please check out this Top 10 patent cliff
Patent cliff, one happy and one sad.
2023-03-21 10:46 -
Pril Pharma: Second contrast agent FDA Approval after iodoparol injection!
Gadobul injection was approved by the US FDA.
2023-03-21 10:39 -
J. Med. Chem. | new BTK - PROTACs: blood system lymphoma treatment of new ideas
Pay attention to the most advanced scientific research achievements in the field of protein degradation!
2023-03-17 11:13 -
After 20 years of failure, Is there Hope for targeted Aβ therapy for AD?
Lilly Solanezumab was a 10-year phase 3 failure.
2023-03-17 11:10
Hot News
- SABIC Shuts Down 865,000-Ton U... Jul 02, 2025
- European Petrochemical Industr... Jun 26, 2025
- ExxonMobil Launches $10 Billio... Jul 17, 2025
- Malaysia Proposes Major Food R... Jun 26, 2025
- The Truth Behind the US-China ... Jun 30, 2025
Related Products
Related Producers
